Published in Transpl Int on January 01, 2005
Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int J Clin Oncol (2008) 1.37
Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines. Br J Cancer (2011) 1.33
Endothelial Akt signaling is rate-limiting for rapamycin inhibition of mouse mammary tumor progression. Cancer Res (2007) 1.32
Long-term blood vessel removal with combined laser and topical rapamycin antiangiogenic therapy: implications for effective port wine stain treatment. Lasers Surg Med (2010) 1.21
Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo. Mol Ther (2007) 1.16
A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. Clin Cancer Res (2010) 1.09
Rapamycin induces regression of endometriotic lesions by inhibiting neovascularization and cell proliferation. Br J Pharmacol (2006) 1.03
Proangiogenic stimulation of bone marrow endothelium engages mTOR and is inhibited by simultaneous blockade of mTOR and NF-kappaB. Blood (2005) 0.86
Efficacy and comparative effectiveness of sirolimus as an anticancer drug. Laryngoscope (2011) 0.82
Trilayer micelles for combination delivery of rapamycin and siRNA targeting Y-box binding protein-1 (siYB-1). Biomaterials (2013) 0.81
mTOR Signaling Cascade in Psoriatic Disease: Double Kinase mTOR Inhibitor a Novel Therapeutic Target. Indian J Dermatol (2014) 0.80
Rapamycin inhibits VEGF-induced microvascular hyperpermeability in vivo. Microcirculation (2010) 0.79
Combined inhibition of Dnmt and mTOR signaling inhibits formation and growth of colorectal cancer. Int J Colorectal Dis (2009) 0.79
Pharmacokinetics of orally administered low-dose rapamycin in healthy dogs. Am J Vet Res (2016) 0.77
Temsirolimus and chloroquine cooperatively exhibit a potent antitumor effect against colorectal cancer cells. J Cancer Res Clin Oncol (2014) 0.77
Tumour growth of colorectal rat liver metastases is inhibited by hepatic arterial infusion of the mTOR-inhibitor temsirolimus after portal branch ligation. Clin Exp Metastasis (2015) 0.76
The cannabinoid CB1 receptor and mTORC1 signalling pathways interact to modulate glucose homeostasis in mice. Dis Model Mech (2015) 0.75
Portal branch ligation does not counteract the inhibiting effect of temsirolimus on extrahepatic colorectal metastatic growth. Clin Exp Metastasis (2017) 0.75
Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg (2012) 19.78
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med (2002) 7.06
Effects of donor pretreatment with dopamine on graft function after kidney transplantation: a randomized controlled trial. JAMA (2009) 3.83
A new pumpless extracorporeal interventional lung assist in critical hypoxemia/hypercapnia. Crit Care Med (2006) 3.24
Acute mesenteric ischemia: a vascular emergency. Dtsch Arztebl Int (2012) 2.70
Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol (2010) 2.66
Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology (2009) 2.64
Dynamic imaging of cancer growth and invasion: a modified skin-fold chamber model. Histochem Cell Biol (2008) 2.39
Temporary intraoperative porto-caval shunt: useless or beneficial in piggy back liver transplantation? Transpl Int (2012) 2.17
Loss of liver transplant surgeons into alternate career paths. Transpl Int (2014) 2.04
Multicentric evaluation of model for end-stage liver disease-based allocation and survival after liver transplantation in Germany--limitations of the 'sickest first'-concept. Transpl Int (2010) 1.99
The German hospital malnutrition study. Clin Nutr (2006) 1.93
Hepatocyte entry leads to degradation of autoreactive CD8 T cells. Proc Natl Acad Sci U S A (2011) 1.89
Interleukin 21 controls tumour growth and tumour immunosurveillance in colitis-associated tumorigenesis in mice. Gut (2011) 1.84
Evaluation of clinical safety and beneficial effects of a fish oil containing lipid emulsion (Lipoplus, MLF541): data from a prospective, randomized, multicenter trial. Crit Care Med (2007) 1.80
Overture for growth hormone: requiem for interleukin-6? Crit Care Med (2007) 1.69
Induction of IL-13 triggers TGF-beta1-dependent tissue fibrosis in chronic 2,4,6-trinitrobenzene sulfonic acid colitis. J Immunol (2007) 1.69
Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation (2004) 1.68
Endoscopic vacuum-assisted closure of anastomotic leakage following anterior resection of the rectum: a new method. Surg Endosc (2007) 1.68
Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Transplantation (2006) 1.64
Fatal pneumonia caused by Panton-Valentine Leucocidine-positive methicillin-resistant Staphylococcus aureus (PVL-MRSA) transmitted from a healthy donor in living-donor liver transplantation. Transplantation (2006) 1.63
Intestinal ischemia: current treatment concepts. Langenbecks Arch Surg (2010) 1.60
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation (2016) 1.59
Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I/II trial. Onkologie (2011) 1.57
Bile duct damage after cold storage of deceased donor livers predicts biliary complications after liver transplantation. J Hepatol (2013) 1.56
Use of biosynthetic prosthesis (Omniflow II®) to replace infected infrainguinal prosthetic grafts--first results. Vasa (2012) 1.55
Quality of life and functional long-term outcome after partial pancreatoduodenectomy: pancreatogastrostomy versus pancreatojejunostomy. Ann Surg Oncol (2005) 1.52
IL-13 signaling via IL-13R alpha2 induces major downstream fibrogenic factors mediating fibrosis in chronic TNBS colitis. Gastroenterology (2008) 1.51
Shedding light on the elusive role of endothelial cells in cytomegalovirus dissemination. PLoS Pathog (2011) 1.51
Completion thyroidectomy: effect of timing on clinical complications and oncologic outcome in patients with differentiated thyroid cancer. World J Surg (2012) 1.50
Tumour nephrectomy with vena cava thrombus. BJU Int (2005) 1.43
Cytomegalovirus in transplantation - challenging the status quo. Clin Transplant (2007) 1.43
High volume naked DNA tail-vein injection restores liver function in Fah-knock out mice. J Gastroenterol Hepatol (2010) 1.42
The challenge of pancreatic anastomosis. Langenbecks Arch Surg (2008) 1.41
Kidney transplant in children weighing less than 15 kg: donor selection and technical considerations. Transplantation (2002) 1.41
Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation (2004) 1.40
Pumpless extracorporeal interventional lung assist in patients with acute respiratory distress syndrome: a prospective pilot study. Crit Care (2009) 1.40
Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Metastasis Rev (2007) 1.38
Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer. Clin Cancer Res (2008) 1.35
Immunological effects of laparoscopic vs open colorectal surgery: a prospective clinical study. Arch Surg (2005) 1.35
Peritoneal carcinomatosis: patients selection, perioperative complications and quality of life related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol (2009) 1.34
The liver: a special case in transplantation tolerance. Semin Liver Dis (2007) 1.33
EFEMP1 expression promotes in vivo tumor growth in human pancreatic adenocarcinoma. Mol Cancer Res (2009) 1.33
Google goes cancer: improving outcome prediction for cancer patients by network-based ranking of marker genes. PLoS Comput Biol (2012) 1.32
Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer (2007) 1.30
Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo. Mol Cancer Ther (2007) 1.29
Surgical strategy in aortoesophageal fistulae: endovascular stentgrafts and in situ repair of the aorta with cryopreserved homografts. Ann Surg (2007) 1.29
Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice. Clin Cancer Res (2004) 1.28
Standardization of whole blood immune phenotype monitoring for clinical trials: panels and methods from the ONE study. Transplant Res (2013) 1.27
Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer. Mol Cancer Ther (2011) 1.26
Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-alpha 2. Cancer Res (2008) 1.26
Cutting Edge: Immunological consequences and trafficking of human regulatory macrophages administered to renal transplant recipients. J Immunol (2011) 1.25
Tumor development in murine ulcerative colitis depends on MyD88 signaling of colonic F4/80+CD11b(high)Gr1(low) macrophages. J Clin Invest (2011) 1.25
mTOR, cancer and transplantation. Am J Transplant (2008) 1.24
A cell-based approach to the minimization of immunosuppression in renal transplantation. Transpl Int (2008) 1.24
Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer (2005) 1.22
Multipotent mesenchymal stem cells acquire a lymphendothelial phenotype and enhance lymphatic regeneration in vivo. Circulation (2008) 1.22
Insulin attenuates the systemic inflammatory response to thermal trauma. Mol Med (2002) 1.22
Prothrombin complex concentrate in surgical patients: retrospective evaluation of vitamin K antagonist reversal and treatment of severe bleeding. Crit Care (2009) 1.21
Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors. Cancer (2003) 1.20
GFP-transfected tumor cells are useful in examining early metastasis in vivo, but immune reaction precludes long-term tumor development studies in immunocompetent mice. Clin Exp Metastasis (2003) 1.19
Vascular endothelial growth factor in esophageal cancer. J Surg Oncol (2004) 1.19
The prognostic value of lymph node ratio in a population-based collective of colorectal cancer patients. Ann Surg (2010) 1.18
Estimation of liver size for liver transplantation: the impact of age and gender. Liver Transpl (2004) 1.18
Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF. Blood (2005) 1.17
Cancer stem cells: how can we target them? Curr Med Chem (2008) 1.17
Transplant acceptance-inducing cells as an immune-conditioning therapy in renal transplantation. Transpl Int (2008) 1.17
Comparison of laparoscopic vs. open access surgery in patients with rectal cancer: a prospective analysis. Dis Colon Rectum (2008) 1.17
Toward MSC in solid organ transplantation: 2008 position paper of the MISOT study group. Transplantation (2009) 1.16
Determinants of morbidity and survival after elective non-curative resection of stage IV colon and rectal cancer. Int J Colorectal Dis (2009) 1.16
Charitable State-Controlled Foundation Human Tissue and Cell Research: Ethic and Legal Aspects in the Supply of Surgically Removed Human Tissue For Research in the Academic and Commercial Sector in Germany. Cell Tissue Bank (2003) 1.16
EFEMP1 binds the EGF receptor and activates MAPK and Akt pathways in pancreatic carcinoma cells. Biol Chem (2009) 1.15
IFN-γ-induced iNOS expression in mouse regulatory macrophages prolongs allograft survival in fully immunocompetent recipients. Mol Ther (2012) 1.14
Deletion of Foxp3+ regulatory T cells in genetically targeted mice supports development of intestinal inflammation. BMC Gastroenterol (2012) 1.13
Activating transcription factor-3 (ATF3) functions as a tumor suppressor in colon cancer and is up-regulated upon heat-shock protein 90 (Hsp90) inhibition. BMC Cancer (2010) 1.12
Macrophages driven to a novel state of activation have anti-inflammatory properties in mice. J Immunol (2008) 1.10